Skip to Main Content
Search this site:
Register
Sign-in
Home
Latest Advances
Publications
News
Tell us your thoughts
Photo Gallery
Video Gallery
Development Phases
Basic Science
Clinical Development
Regulatory
Venture Capital
Exit Partners
Events
For Patients
Forums
Product Reviews
About
Contact
Partners
What are the best ways to de-risk Dry Eye product development?
Main-tags:
Venture Capital
Sub-tags:
Steve Elms
,
Emmett Cunningham
,
Dayton Misfledt
,
Dana Ono
,
Cedric Bisson
Video tags:
Dry Eye Summit 2010
,
Venture Capital
Related Videos
Does it make sense to invest in Dry Eye?
At which development stage do investors consider an investment in a Dry Eye product?
At which development stage do investors consider an investment in a Dry Eye product?
At which development stage are you most likely to find an exit partner?
What will the Dry Eye landscape look like in 3 to 5 years?
As an investor, how open are you to "virtual" Dry Eye companies, versus "bricks and mortar" ones?
Is there an 'innovation gap' between early-stage and late-stage Dry Eye development?
How much pre-clinical data do Dry Eye companies need to attract funding?
How is better understanding of biomarkers and patient segmentation affecting investment
How do investors assess the opportunities? Do they prefer Rx to OTC?
